Evidence map›Paper›PMID 40194915›Full record

ReviewZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2025

[Research of tricuspid regurgitation associated with cardiac implantable electronic devices].

Danqing Yu, Yan Lin, Qi Chen, Xianbao Liu, Jian'an Wang

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Danqing YuDepartment of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Transvascular Implantation Devices, Zhejiang Provincial Key Laboratory of Cardiovascular Disease Diagnosis and Treatment, Hangzhou 310009, China. y222180237@zju.edu.cn.
Yan LinDepartment of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Transvascular Implantation Devices, Zhejiang Provincial Key Laboratory of Cardiovascular Disease Diagnosis and Treatment, Hangzhou 310009, China.
Qi ChenDepartment of Cardiovascular Intervention, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Xianbao LiuDepartment of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Transvascular Implantation Devices, Zhejiang Provincial Key Laboratory of Cardiovascular Disease Diagnosis and Treatment, Hangzhou 310009, China. liuxb@zju.edu.cn.
Jian'an WangDepartment of Cardiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Transvascular Implantation Devices, Zhejiang Provincial Key Laboratory of Cardiovascular Disease Diagnosis and Treatment, Hangzhou 310009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tricuspid regurgitation associated with cardiac implantable electronic devices (CIED) constitutes a significant subset of secondary tricuspid regurgitation, characterized by a multifactorial etiology involving pacing lead-mediated mechanical interference and CIED-related systemic factors. The pathogenesis of CIED-related tricuspid regurgitation encompasses direct mechanical trauma or functional disruption of the tricuspid valve apparatus by pacing leads, pacing mode-induced hemodynamic alterations, and clinical risk factors such as permanent atrial fibrillation, apical pacing, and high right ventricular pacing burden. The natural progression and clinical outcomes of CIED-related tricuspid regurgitation parallel those of tricuspid regurgitation stemming from other etiologies. Advanced imaging modalities, including echocardiography, cardiac computed tomography, and cardiac magnetic resonance imaging, enable precise diagnosis and longitudinal assessment of CIED-related tricuspid regurgitation. Management strategies emphasize multidisciplinary collaboration as well as integration of preventive approaches-such as refined lead implantation techniques and tailored pacing modalities-with therapeutic interventions ranging from pharmacotherapy to surgical valve repair or replacement. This article reviews the current understanding of CIED-related tricuspid regurgitation to provide a reference for clinical practice and research.

Indexed as

Defibrillators, ImplantablePacemaker, ArtificialTricuspid Valve InsufficiencyHumansCardiac implantable electronic devicesDiagnosisManagementPathogenesisPreventionReviewTricuspid regurgitation

Identifiers

PMID40194915
PMCPMC12062947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.